Oragenics, Inc. in brief
Oragenics, Inc. is a listed company in the Biotechnology industry, based in Lakewood Ranch, Florida, USA. Its last known market value was $18 M (December 2022); there is no current figure. Its shares trade under the symbol UAVP.F (Frankfurt).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Oragenics, Inc. timeline
- 2002
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- 💰Record revenue of $0 millionFY2022, the highest of the 3 years on record.
Events of Oragenics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,797 (Jan 2022) · #5,334 (Dec 2022)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -118.8%
- Liabilities / assets
- 17.8%
- Revenue growth
- -69.2%
- R&D / revenue
- 38725.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-9M | $-10M | — |
| Dec 2024 | — | — | $-11M | $-11M | — |
| Dec 2023 | $0M | -69.2% | $-21M | $-21M | -51650.0% |
| Dec 2022 | $0M | +44.4% | $-14M | $-14M | -10992.3% |
| Dec 2021 | $0M | — | $-16M | $-16M | -17455.6% |
| Dec 2020 | — | — | $-27M | $-26M | — |
| Dec 2019 | — | — | $-16M | $-16M | — |
| Dec 2018 | — | — | $-10M | $-10M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-9M | — | — | $-4.56 | — |
| Dec 2024 | $-9M | — | — | $-47.88 | — |
| Dec 2023 | $-7M | — | — | $-9.18 | — |
| Dec 2022 | $-15M | $0M | $-15M | $-7.11 | — |
| Dec 2021 | $-13M | $0M | $-14M | $-0.14 | — |
| Dec 2020 | $-17M | — | — | $-0.47 | — |
| Dec 2019 | $-13M | $0M | $-13M | $-0.37 | — |
| Dec 2018 | $-9M | $0M | $-9M | $-0.87 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Sep 16, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 28, 20268-KCurrent reportListing notice · Other events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jul 6, 20268-KCurrent reportMaterial agreement · Directors or officers changed · Shareholder vote
- May 20, 2026DEF 14AProxy statement
- May 19, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 8, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportOther events
- Apr 13, 20268-KCurrent reportOther events
- Mar 31, 20268-KCurrent report
- Mar 16, 202610-KAnnual report · period to Dec 2025
Official filings of Oragenics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-9 M
- Net income
- $-10 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $10 M
- Total liabilities
- $2 M
- Total equity
- $8 M
As of December-2025
Insider trading at Oragenics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Fred TellingDirector | Sellamended | -210 | $0.940 | $197 | 948 | Form 4/A |
| filed | Fred TellingDirector | Sell | -210 | $0.940 | $197 | 34,538 | Form 4 |
| filed | Odyssey Health, Inc.10% owner | Sell | -5,044 | $4.260 | $21 K | 0 | Form 4 |
| filed | Odyssey Health, Inc.10% owner | Sell | -2,000 | $4.460 | $9 K | 5,044 | Form 4 |
| filed | Odyssey Health, Inc.10% owner | Sell | -5,000 | $4.450 | $22 K | 7,044 | Form 4 |
| filed | Odyssey Health, Inc.10% owner | Sell | -5,000 | $4.270 | $21 K | 12,044 | Form 4 |
| filed | Robert C. KoskiDirector | Conversionindirect | +5,000 | — | — | 23,367 | Form 4 |
| filed | Alan W. DuntonDirector | Sell | -66 | $0.360 | $24 | 25,623 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Oragenics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split
Trading halts
- 2025-07-01 12:02 UTC, code T3, resumed 12:50 UTC
- 2025-06-03 13:45 UTC, code M, resumed 13:50 UTC
- 2025-06-03 13:39 UTC, code M, resumed 13:44 UTC
- 2025-06-03 13:33 UTC, code M, resumed 13:38 UTC
Fails to deliver
- : 128 shares at $0.37
- : 4,957 shares at $0.37
- : 133 shares at $0.40
- : 133 shares at $0.42
- : 3,566 shares at $0.41
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Oragenics, Inc. scorecard#
Passes 1 of the 6 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.56 vs -47.88Diluted EPS -4.56 in fiscal 2025 against -47.88 the year before (report's currency).
- ✓Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against -$26 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-243.9%-243.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Oragenics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | 0.0−71.4%100% | 0.1+51.2%100% | 0.1—100% | — | — | — | 0—— | 0—— | |
| Cost of revenue | — | — | — | — | — | — | — | — | 0—— | 0—— | |
| Gross profit | — | — | — | — | — | — | — | — | 0—— | 0—— | |
| Research and development | 2.4−41.8%— | 4.1−73.4%— | 15+53.8%41140% | 10−4.9%7659% | 11−52.1%12170% | 22+82.4%— | 12+103%— | 6.0+68.7%— | 3.5−25.6%— | 4.8—— | |
| General and administrative | 7.0+8.2%— | 6.4+18.2%— | 5.5+21.7%14479% | 4.5r4.5−15.0%3406% | 5.3+16.3%6061% | 4.5+20.7%— | 3.8−6.6%— | 4.0+26.5%— | 3.2−16.1%— | 3.8—— | |
| Operating expenses | 9.4−11.3%— | 11−49.6%— | 21+43.9%55620% | 15r15−8.2%11065% | 16−40.5%18230% | 27+67.8%— | 16+58.9%— | 10.0+48.8%— | 6.7−21.4%— | 8.5—— | |
| Operating income | −9.4—— | −11—— | −21—−55520% | −14r−14—−10965% | −16—−18130% | −27—— | −16—— | −10.0—— | −6.7—— | −8.5—— | |
| Interest and finance income | 0.2+297%— | 0.0−78.2%— | 0.2+54.8%559% | 0.1+79.2%103% | 0.1−15.1%87.2% | 0.1−72.1%— | 0.3+270%— | 0.1+747%— | 0.0−74.5%— | 0.0—— | |
| Interest expense and finance costs | 0.8+2535%— | 0.0−2.5%— | 0.0+103%81.2% | 0.0−4.1%11.5% | 0.0+47.5%18.1% | 0.0+46.4%— | 0.0+26.2%— | 0.0−97.3%— | 0.2+5156%— | 0.0—— | |
| Other non-operating income (expense) | −0.6—— | −0.0−104%— | 0.2+88.2%662% | 0.1r0.1+123%101% | 0.1−71.8%68.3% | 0.2−32.4%— | 0.3+289%— | 0.1—— | −0.0−129%— | 0.0—— | |
| Income before tax | −10.0—— | −11—— | −21—−54858% | −14—−10864% | −16—−18062% | −26—— | −16—— | −9.9—— | −6.7—— | −8.5—— | |
| Income tax | −0.1—— | — | — | — | — | — | — | 0—— | 0—— | 0—— | |
| Income from continuing operations | — | — | — | — | — | — | — | — | −6.7—— | −8.5—— | |
| Income from discontinued operations | — | — | — | — | — | — | — | — | — | 1.5—— | |
| Net income attributable to shareholders | −9.8—— | −11—— | −21—−54858% | −14—−10864% | −16—−18062% | −26—— | −16—— | −9.9—— | −6.7—— | −7.0—— | |
| Earnings per share, basic | -4.56—— | -47.88r-1.60—— | -9.18—— | -7.11—— | -8.09r-0.14—— | -0.47—— | -0.37—— | -0.87—— | -1.37—— | -1.57r-0.16—— | |
| Earnings per share, diluted | -4.56—— | -47.88r-1.60—— | -9.18—— | -7.11—— | -0.14—— | -0.47—— | -0.37—— | -0.87—— | -1.37—— | -1.57r-0.16—— | |
| Shares, weighted average (basic) | 2.2+877%— | 0.2r6.6−90.2%— | 2.2+12.0%— | 2.0+3.4%— | 1.9r113−96.6%— | 57—— | — | — | — | — | |
| Shares, weighted average (diluted) | 2.2+877%— | 0.2r6.6−90.2%— | 2.2+12.0%— | 2.0−98.2%— | 113+99.7%— | 57+33.7%— | 42+224%— | 13+165%— | 4.9+10.4%— | 4.5r45—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 4.4+409%43.7% | 0.9−75.2%58.7% | 3.5−69.5%70.1% | 11−58.1%77.4% | 27+54.6%96.6% | 18−3.4%94.4% | 18−9.6%92.5% | 20+228%91.6% | 6.2+51.1%85.5% | 4.1—94.7% | |
| Short-term investments | 4.0—39.7% | — | — | — | — | — | — | — | — | — | |
| Receivables | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Inventory | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Other current assets | 1.6+166%16.0% | 0.6+59.0%41.3% | 0.4−86.6%7.7% | 2.9r2.9+559%19.4% | 0.4+26.7%1.5% | 0.3−39.8%1.8% | 0.6−67.0%2.9% | 1.7+68.0%7.8% | 1.0+628%14.2% | 0.1—3.3% | |
| Current assets | 10+584%100% | 1.5−61.9%100% | 3.9−72.9%77.8% | 14r14−48.4%96.8% | 28+54.1%98.1% | 18−4.5%96.3% | 19−14.1%95.4% | 22+205%99.5% | 7.2+70.4%99.7% | 4.2—98.0% | |
| Property, plant and equipment | — | — | 0−100%0.0% | 0.1+165%0.8% | 0.0+7.0%0.2% | 0.0−53.6%0.2% | 0.1−20.9%0.5% | 0.1+437%0.5% | 0.0−75.2%0.3% | 0.1—2.0% | |
| Right-of-use (leased) assets | — | — | 0.0−97.2%0.2% | 0.3−27.3%2.4% | 0.5−27.1%1.7% | 0.7−20.4%3.5% | 0.8—4.2% | — | — | — | |
| Total assets | 10+584%100% | 1.5−70.4%100% | 5.0−66.3%100% | 15−47.7%100% | 28+51.1%100% | 19−5.4%100% | 20−10.4%100% | 22+206%100% | 7.2+67.4%100% | 4.3—100% | |
| Accounts payable | 1.6+36.2%15.5% | 1.1−8.1%77.7% | 1.2+405%25.1% | 0.2−71.1%1.7% | 0.9r0.9+159%3.0% | 0.3r0.3−72.6%1.8% | 1.2r1.2+45.7%6.1% | 0.8r0.8+34.0%3.8% | 0.6r0.6+34.0%8.6% | 0.5r0.5—10.7% | |
| Customer deposits | — | — | — | 0.00.0%0.1% | 0.0—0.1% | — | — | — | — | — | |
| Current liabilities | — | — | 1.8+12.6%36.2% | 1.6+10.4%10.8% | 1.4+7.7%5.1% | 1.3−27.5%7.2% | 1.9+58.5%9.4% | 1.2+29.9%5.3% | 0.9−33.1%12.5% | 1.3—31.2% | |
| Lease liabilities (non-current) | — | — | — | 0.2−49.1%1.0% | 0.3−39.3%1.1% | 0.5−26.4%2.6% | 0.7—3.4% | — | — | — | |
| Non-current liabilities | — | — | — | 0.2−49.1%1.0% | 0.3−39.3%1.1% | 0.5−26.4%2.6% | 0.7—3.4% | — | — | — | |
| Total liabilities | 1.8+6.1%17.7% | 1.7−6.3%114% | 1.8—36.2% | — | — | — | — | — | — | — | |
| Retained earnings | −227—−2251% | −217—−14722% | −206—−4152% | −186—−1257% | −171—−607% | −154—−827% | −127—−645% | −111—−505% | −101—−1405% | −95—−2197% | |
| Shareholders' equity | 8.3—82.3% | −0.2−107%−14.4% | 3.2−75.6%63.8% | 13−50.9%88.2% | 26+57.2%93.8% | 17−2.2%90.2% | 17−17.5%87.2% | 21+231%94.7% | 6.3+113%87.5% | 3.0—68.8% | |
| Total liabilities and equity | 10+584%100% | 1.5−70.4%100% | 5.0−66.3%100% | 15−47.7%100% | 28+51.1%100% | 19−5.4%100% | 20−10.4%100% | 22+206%100% | 7.2+67.4%100% | 4.3—100% | |
| Shares outstanding | 4.3+919%— | 0.4r13−86.4%— | 3.1+52.2%— | 2.0+1.1%— | 2.0r116−97.8%— | 92+99.0%— | 46+56.7%— | 29+497%— | 4.9+0.3%— | 4.9r49—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | 0.0−38.7%72.7% | 0.0+8.3%34.0% | 0.0−20.2%47.4% | 0.1−17.4%— | 0.1+108%— | 0.0−54.2%— | 0.1−12.3%— | 0.1—— | |
| Share-based compensation | 0.6+24.5%— | 0.5−49.2%— | 1.0+37.0%2701% | 0.7−56.0%564% | 1.7+13.2%1941% | 1.5+170%— | 0.6−44.5%— | 1.0—— | — | — | |
| Cash from operating activities | −9.2—— | −8.6—— | −7.3—−19363% | −15—−11579% | −13—−15485% | −17—— | −13—— | −9.1—— | −6.4—— | −7.1—— | |
| Capital expenditure | — | — | — | −0.1—−97.0% | −0.0—−50.4% | — | −0.0—— | −0.1—— | — | −0.0—— | |
| Cash from investing activities | — | — | −0.9—−2487% | −0.1—−87.8% | −0.0—−50.4% | — | −0.0—— | −0.1—— | — | 1.7—— | |
| Debt issued | 2.2—— | — | — | — | — | — | — | — | — | — | |
| Shares issued | 2.6−60.5%— | 6.7—— | — | 0.1−99.7%52.7% | 27+135%30667% | 11—— | — | 14—— | — | 2.6—— | |
| Cash from financing activities | 17+181%— | 6.0+2006%— | 0.3—754% | −0.5−102%−376% | 23+41.8%26602% | 16+47.1%— | 11−52.3%— | 23+175%— | 8.4+89.8%— | 4.5—— | |
| Change in cash | 7.5—— | −2.6—— | −7.9—−21096% | −16−265%−12043% | 9.6—11066% | −0.6—— | −1.9−114%— | 14+573%— | 2.1—— | −0.9—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Research and development | 4.1+20.1%— | 1.6+69.3%— | 1.2+162%— | 0.6+89.0%— | 0.7*−59.7%— | 0.9+5.9%— | 0.4−50.4%— | 0.3−48.5%— | 1.7*−84.9%— | 0.9—— | 0.9—— | 0.7—— | 11*—— | |
| General and administrative | 5.9−14.0%— | 1.0−53.5%— | 1.4+12.0%— | 1.6−4.4%— | 1.8*+8.1%— | 2.2+40.7%— | 1.3−9.6%— | 1.7−6.2%— | 1.7*−3.7%— | 1.6—— | 1.4—— | 1.8—— | 1.8*—— | |
| Operating expenses | 9.9−2.7%— | 2.6−16.9%— | 2.6+51.2%— | 2.3+11.3%— | 2.5*−25.5%— | 3.1+28.2%— | 1.7−25.7%— | 2.0−17.6%— | 3.4*−73.8%— | 2.4—— | 2.3—— | 2.5—— | 13*—— | |
| Operating income | −9.9—— | −2.6—— | −2.6—— | −2.3—— | −2.5*—— | −3.1—— | −1.7—— | −2.0—— | −3.4*—— | −2.4—— | −2.3—— | −2.5—— | −13*—— | |
| Interest and finance income | 0.2+62.3%— | 0.0−79.6%— | 0.0+78.8%— | 0.0+301%— | 0.1*+707%— | 0.1+620%— | 0.0+162%— | 0.0−47.0%— | 0.0*−72.1%— | 0.0—— | 0.0—— | 0.0—— | 0.0*—— | |
| Interest expense and finance costs | 0.0−97.7%— | 0.0−6.9%— | 0.0−99.9%— | 0.0−98.1%— | 0.0*−32.0%— | 0.0−29.4%— | 0.6+31642%— | 0.2+2711%— | 0.0*−10.3%— | 0.0—— | 0.0—— | 0.0—— | 0.0*—— | |
| Other non-operating income (expense) | 0.1—— | −0.0−149%— | 0.0—— | 0.0—— | 0.1*+1081%— | 0.1—— | −0.6−61400%— | −0.2−2158%— | 0.0*−87.1%— | −0.0—— | 0.0—— | 0.0—— | 0.0*—— | |
| Income before tax | −9.8—— | −2.6—— | −2.6—— | −2.2—— | −2.4*—— | −3.1—— | −2.3—— | −2.2—— | −3.3*—— | −2.5—— | −2.3—— | −2.5—— | −13*—— | |
| Income tax | — | −0.0—— | −0.0—— | −0.0—— | — | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −9.6—— | −2.6—— | −2.5—— | −2.2—— | −2.3*—— | −3.1—— | −2.3—— | −2.2—— | −3.3*—— | −2.5—— | −2.3—— | −2.5—— | −13*—— | |
| Earnings per share, basic | — | -0.58—— | -0.57—— | -0.51—— | — | -1.96—— | -3.10—— | -3.65r-0.12—— | — | -11.32r-0.38—— | -15.27r-0.51—— | -0.70—— | — | |
| Earnings per share, diluted | — | -0.58—— | -0.57—— | -0.51—— | — | -1.96—— | -3.10—— | -3.65r-0.12—— | — | -11.32r-0.38—— | -15.27r-0.51—— | -0.70—— | — | |
| Shares, weighted average (basic) | 4.5+189%— | 4.5+189%— | 4.4+505%— | 4.3+608%— | — | 1.6+617%— | 0.7+385%— | 0.6r18−82.6%— | — | 0.2r6.5—— | 0.2r4.5—— | 3.5—— | — | |
| Shares, weighted average (diluted) | 4.5+189%— | 4.5+189%— | 4.4+505%— | 4.3+608%— | — | 1.6+617%— | 0.7+385%— | 0.6r18−82.6%— | — | 0.2r6.5—— | 0.2r4.5—— | 3.5—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2.2—67.9% | 2.2−80.5%67.9% | 3.9+95.8%70.4% | 6.1+78.5%81.5% | 4.4+409%43.7% | 11+263%89.8% | 2.0+46.4%92.2% | 3.4+65.1%88.4% | 0.9−75.2%58.7% | 3.1—60.4% | 1.3—49.8% | 2.1—58.6% | 3.5—70.1% | |
| Short-term investments | — | — | — | — | 4.0—39.7% | — | — | — | — | — | — | — | — | |
| Other current assets | 1.1—32.1% | 1.1−19.0%32.1% | 1.6+25.3%29.6% | 1.4+209%18.5% | 1.6+166%16.0% | 1.3+34.3%10.2% | 1.3r0.2+381%60.8% | 0.4+20.7%11.6% | 0.6+59.0%41.3% | 1.0—18.6% | 0.3—10.0% | 0.4—10.5% | 0.4—7.7% | |
| Current assets | 3.3—100% | 3.3−74.2%100% | 5.5+157%100% | 7.5+93.6%100% | 10+584%100% | 13+209%100% | 2.1+32.2%100% | 3.9+58.4%100% | 1.5−61.9%100% | 4.1—79.0% | 1.6—59.7% | 2.4—69.1% | 3.9—77.8% | |
| Property, plant and equipment | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | — | — | — | — | — | 0.0—0.2% | |
| Total assets | 3.3—100% | 3.3−74.2%100% | 5.5+157%100% | 7.5+93.6%100% | 10+584%100% | 13+144%100% | 2.1−21.0%100% | 3.9+9.5%100% | 1.5−70.4%100% | 5.2—100% | 2.7—100% | 3.5—100% | 5.0—100% | |
| Accounts payable | 1.8—54.6% | 1.8−27.7%54.6% | 1.8+43.7%33.2% | 1.3+62.0%16.7% | 1.6+36.2%15.5% | 2.5+63.8%19.5% | 1.3+7.4%59.2% | 0.8+11.0%20.0% | 1.1−8.1%77.7% | 1.5—29.1% | 1.2—43.6% | 0.7—19.7% | 1.2—25.1% | |
| Current liabilities | — | — | — | — | — | — | — | — | — | — | — | — | 1.8—36.2% | |
| Total liabilities | 2.2—66.7% | 2.2−23.8%66.7% | 1.8−57.3%33.2% | 1.3−64.9%17.5% | 1.8+6.1%17.7% | 2.9+35.2%22.6% | 4.3+208%199% | 3.7+311%96.4% | 1.7−6.3%114% | 2.1—40.9% | 1.4—51.1% | 0.9—25.7% | 1.8—36.2% | |
| Retained earnings | −234—−7129% | −234—−7129% | −231—−4212% | −229—−3055% | −227—−2251% | −224—−1766% | −221—−10341% | −219—−5660% | −217—−14722% | −213—−4101% | −211—−7786% | −209—−5905% | −206—−4152% | |
| Shareholders' equity | 1.1—33.3% | 1.1−88.9%33.3% | 3.7—66.8% | 6.2+4390%82.5% | 8.3—82.3% | 9.8+219%77.4% | −2.1−260%−99.4% | 0.1−94.8%3.6% | −0.2−107%−14.4% | 3.1—59.1% | 1.3—48.9% | 2.6r2.6—74.3% | 3.2—63.8% | |
| Total liabilities and equity | 3.3—100% | 3.3−74.2%100% | 5.5+157%100% | 7.5+93.6%100% | 10+584%100% | 13+144%100% | 2.1−21.0%100% | 3.9+9.5%100% | 1.5−70.4%100% | 5.2—100% | 2.7—100% | 3.5—100% | 5.0—100% | |
| Shares outstanding | 4.5—— | 4.5+9.3%— | 4.5+448%— | 4.4−79.6%— | 4.3+919%— | 4.1−56.0%— | 0.8−85.3%— | 21+379%— | 0.4r13−86.4%— | 9.4—— | 5.6—— | 4.5—— | 3.1—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Share-based compensation | 0.7+662%— | 0.0*+316%— | 0.0*+159%— | 0.0−1.8%— | 0.6*+961%— | 0.0*−98.2%— | 0.0*−88.4%— | 0.0−74.5%— | 0.1*−87.7%— | 0.3—— | 0.1—— | 0.1—— | 0.5*—— | |
| Cash from operating activities | −9.3—— | −2.0*—— | −2.2*—— | −2.2—— | −2.8*—— | −3.0*—— | −1.3*—— | −2.1—— | −2.0*—— | −2.0*—— | −1.5*—— | −3.1—— | −1.1*—— | |
| Cash from investing activities | — | 0*—— | 0*—— | 4.0—— | — | — | — | — | — | — | — | — | −1.0*—— | |
| Debt issued | — | — | — | — | 0*—— | 0*—— | 0*—— | 2.2—— | — | — | — | — | — | |
| Shares issued | 0.1−97.0%— | 0*—— | 0*—— | 0.1−97.0%— | −0.0*−158%— | 0*−100%— | 0*−100%— | 2.6+43.3%— | 0.0*—— | 3.9*—— | 0.9*—— | 1.8—— | — | |
| Cash from financing activities | 0.1−99.5%— | 0.4*−96.8%— | −0.1*—— | −0.1−102%— | −0.2*—— | 12*+230%— | −0.1*−116%— | 4.7+182%— | −0.3*—— | 3.8*—— | 0.8*—— | 1.7—— | −0.2*—— | |
| Change in cash | — | — | — | — | −3.0*—— | 9.4*+425%— | −1.4*—— | 2.6—— | −2.3*—— | 1.8*—— | −0.7*—— | −1.4—— | −2.3*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Oragenics, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇦🇺 Australia | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Oragenics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $609 K | $407 K | $609 K | $1 |
| 2024Chief executive | $745 K | $280 K | $276 K | — |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Oragenics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 5 · Material agreement 6 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Directors and officersMaterial agreementShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Delisting noticeMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officersMaterial agreementShareholder vote | 8-K | |
| Directors and officersMaterial agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 28, 2026
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2020 | $5 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Apr 2018 | $2 M | Private placement after listing | Under $2 million | 2 | equity, options | SEC |
| Nov 2017 | $7 M | Private placement after listing | $2 to $10 million | 5 | equity | SEC |
| May 2017 | $1 M | Private placement after listing | Under $2 million | 3 | equity | SEC |
| Jun 2016 | $5 M | Private placement after listing | $2 to $10 million | 3 | equity | SEC |
| Sep 2013 | $10 M | Private placement after listing | $2 to $10 million | 1 | equity, debt | SEC |
| Jul 2012 | $13 M | No. 5 | $10 to $50 million | 53 | equity | SEC |
| Jun 2012 | $6 M | No. 4 | $2 to $10 million | 1 | equity | SEC |
| Mar 2012 | $11 M | No. 3 | $10 to $50 million | 1 | equity, debt, options | SEC |
| Jul 2010 | $2 M | No. 2 | $2 to $10 million | 1 | equity, debt | SEC |
| Dec 2009 | $3 M | No. 1 | $2 to $10 million | 9 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Oragenics, Inc.#
$20 K spent on lobbying the US Congress and federal agencies in 2021, most often on defense.
- Defense3 reports
Lobbying firms hired in 2021
American Defense International, Inc. $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2021 | $20 K | — | 4 |
| 2020 | $180 K | — | 5 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Oragenics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Oragenics, Inc. compares in Biotechnology
- Revenue growth-69.2% · higher than 10% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Oragenics, Inc.🇺🇸 | $18 M | — | — | -69.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Dec 25, 2022 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Oragenics, Inc.? Verify and update this profile — free
Show Oragenics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.